Immunomedics (IMMU) Prices 14.286M Share Common Offering at $17.50/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. SPY
7. RXST
8. SPGI
9. RIVN
10. BFH

Go back to Immunomedics (IMMU) Prices 14.286M Share Common Offering at $17.50/Sh

Pre-Open 12/04: (HQY) (CHK) (EXPE) Higher (RVNC) (IMMU) (ZS) Lower (more...)

December 4, 2019 9:19 AM EST

Pre-Open Movers

HealthEquity (NASDAQ: HQY) 14% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.

Chesapeake Energy Corporation (NYSE:... More

After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)

December 3, 2019 6:02 PM EST

After-Hours Movers

HealthEquity (NASDAQ: HQY) 12.7% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.

Revance Therapeutics, Inc. (Nasdaq: RVNC) 10.7% LOWER; announced a proposed underwritten public offering of its common stock. The Company intends to use the net... More

Immunomedics (IMMU) Announces Proposed $250M Public Offering of Common Stock

December 3, 2019 4:02 PM EST

Immunomedics, Inc. (NASDAQ: IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today... More

Immunomedics (IMMU) Resubmits BLA to FDA for Sacituzumab Govitecan

December 3, 2019 8:01 AM EST

Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading... More